Ignite Creation Date:
2024-05-06 @ 5:48 PM
Last Modification Date:
2024-10-26 @ 2:35 PM
Study NCT ID:
NCT05433480
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-07-27
First Post:
2022-06-16
Brief Title:
A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR and HER2- Locally Advanced Recurrent or Metastatic Breast Cancer
Sponsor:
Betta Pharmaceuticals Co Ltd
Organization:
Betta Pharmaceuticals Co Ltd
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-05-25
Start Date Type:
ACTUAL
Primary Completion Date:
2023-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-07-31
Completion Date Type:
ESTIMATED
First Submit Date:
2022-06-16
First Submit QC Date:
June 21 2022
Study First Post Date:
2022-06-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-07-25
Last Update Post Date:
2023-07-27
Last Update Post Date Type:
ACTUAL